___

• 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin, 2011; 61: 69-90. 2. National Comprehensive Cancer Network. Cervical Cancer. (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/ cervical. 3. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer, 2010; 116: 1469-75. 4. Nogami Y, Iida M, Banno K, et al. Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects. Anticancer Res, 2014; 34: 585-92. 5. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet, 2009; 105: 107-8. 6. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol, 2010; 28: 2108-13. 7. Chung H.H., Park N.H., Kim J.W.. Role of integrated PET-CT in pelvic lymph node staging of cervical cancer before radical hysterectomy, Gynecologic & Obstetric Investigation, 2009; 67(1) :61-66. 8. Grueneisen J., Schaarschmidt B.M., Heubner M.. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results, European Journal of Nuclear Medicine & Molecular Imaging, 2015; 42: 1814. 9. Scheidler J, Hricak H, Yu KK, Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA, 1997; 278: 1096-101. 10. Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma. Cancer, 2006; 106: 914–922. 11. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol, 2001; 19:3745–3749. 12. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med, 2006; 354: 496-507. 13. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The Role of FDG-PET Imaging in the Management of Lymphoma. Clin Adv Hematol Oncol, 2004 ;2(2) :115-21. 14. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? in vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med, 1993; 34: 414-19. 15. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer, 2007; 110: 1738-44. 16. Magne N, Chargari C, Vicenzi L, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev, 2008 ;34:671-681. 17. Grigsby PW. The contribution of new imaging techniques in staging cervical cancer. Gynecol Oncol, 2007; 107(1): 10-12. 18. Girardi F, Haas J. The importance of the histologic processing of pelvic lymph nodes in the treatment of cervical cancer. Int J Gynecol Cancer, 1993; 3:12-17. 19. Michel G, Morice P, Castaigne D, Leblanc M, Rey A, Duvillard P. Lymphatic spread in stage Ib and II cervical carcinoma: anatomy and surgical implications. Obstet Gynecol, 1998; 91: 360–363. 20. Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer, 1999; 85:1547-1554. 21. Havrilesky LJ, Kulasingam SL, Matchar DB and Myers ER: FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol, 2005; 97: 183-191. 22. Reinhardt M. J., Ehritt-Braun C., Vogelgesang D., Ihling C., Hogerle S., Mix M., et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.Radiology, 2001; 218: 776-782. 23. Roh J. W., Seo S. S., Lee S., Kang K. W., Kim S. K., Sim J. S., et al. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: a prospective surgicopathologic correlation study. Eur. J. Cancer, 2005; 41: 2086-2092.24. Wright J. D., Dehdashti F., Herzog T. J., Mutch D. G., Huettner P. C., Rader J. S., et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer, 2005;104: 2484–2491. 25. Sironi S., Buda A., Picchio M., Perego P., Moreni R., Pellegrino A., et al. (2006). Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology, 2006; 238: 272–279. 26. Kuan Lv, Hui-min Guo , Ying-jv Lu , Zhi-xing Wu , Ke Zhang and Jian-kui Han. Role of 18F-FDG PET/CT in detecting pelvic lymph-node metastases in patients with early-stage uterine cervical cancer: comparison with MRI findings. Nuclear Medicine Communications, 2014; 35:1204-1211. 27. Belhocine T, Thille A, Fridman V, et al: Contribution of whole-body (18)FDG-PET imaging in the management of cervical cancer. Gynecol Oncol, 2002; 87:90-97. 28. Williams AD, Cousins C, Soutter WP, et al: Detection of pelvic lymph node metastases in gynecologic malignancy: A comparison of CT, MR imaging, and positron emission tomography. AJR Am J Roentgenol, 2001; 177:343-348. 29. Chou H. H., Chang T. C., Yen T. C., Ng K. K., Hsueh S., Ma S. Y., et al. Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J. Clin. Oncol, 2006; 24: 123–128. 30. Tomohito Tanaka; Shun Sasaki; Hiromitsu Tsuchihashi; Yoshito Terai; Kazuhiro Yamamoto; Takashi Yamada; Masahide Ohmichi. Which is better for predicting pelvic lymph node metastases in patients with cervical cancer: Fluorodeoxyglucose-positron emission tomography/computed tomography or a sentinel node biopsy? A retrospective observational study. Medicine. 97(16):e0410, APR 2018. 31. Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol, 2008;190:1652–8. 32. Lukas R, Helena R, Jiri HM, Martin H, Petr S. Current status of sentinel lymph node mapping in the management of cervical cancer. Expert Rev Anticancer Ther, 2013; 13:861–870. 33. Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C et al. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol, 2012; 127:131–135. 34. Lin Qiu, Yue Chen. Comparison between 18F-FDG PET (PET/CT) and sentinel lymph node biopsy in the detection of regional lymph node metastasis of various malignancies: review of the literature Journal of Biomedical Graphics and Computing, 2013; 3 (4): 101-115. 35. Jianjiang Ruan, Yueqiao Zhang, Hong Ren. Meta-analysis of PET/CT Detect Lymph Nodes Metastases of Cervical Cancer. Open Med (Wars), 2018; 13: 436–442.